Association between serum β2-microglobulin and mortality in Japanese peritoneal dialysis patients: A cohort study.

BACKGROUND: Higher serum β2-microglobulin (B2M) concentrations are associated with higher mortality in the general population, non-dialyzed chronic kidney disease patients and patients receiving hemodialysis (HD). However, this relationship among patients on peritoneal dialysis (PD) has not been validated.
METHODS: We collected baseline data for 3,011 prevalent PD patients from a nationwide dialysis registry in Japan at the end of 2010. Clinical outcomes for 9 years were then evaluated using the registry at the end of 2011 to 2019. All-cause and cardiovascular (CV) mortality was assessed using Cox regression analysis and competing-risks regression analysis, respectively. We used multiple imputation to deal with missing covariate data.
RESULTS: During a median follow-up of 87 months, 2,054 patients transferred to combined therapy with PD and HD or HD directly. A total of 3,011 patients, 1,235 (41.0%) died, including 437 patients (14.5%) from CV causes. Among them, 612 patients died after transfer to other dialysis modalities. Univariate analyses revealed no significant association between serum B2M and mortality, whereas higher serum B2M was independently associated with both all-cause and CV mortalities in adjusted models. However, the significant association between serum B2M and CV mortality disappeared in analysis treating serum B2M as a categorical variable. The effect of serum B2M on all-cause mortality was significantly higher among patients with higher urinary volume and a significant interaction was evident.
CONCLUSIONS: Using a large-scale registry, we found that serum B2M contributes tenuously but significantly to worse outcome and residual kidney function significantly affects this relationship. On the contrary, serum B2M per se had no predictive value for patient outcome in prevalent PD patients.

Introduction

In the management of peritoneal dialysis (PD), solute and water removal are monitored to decide the appropriate modality of dialysis. Assessment of solute removal is largely dependent on the measurement of small solute clearance, including Kt/V and creatinine clearance [1]. Although the total Kt/V urea was recommended to be maintained at 1.7 according to a previous clinical guideline [1], a more recent guideline did not establish target small solute clearance, because only a low level of evidence suggests that increasing urea clearance has any impact on quality of life, technique survival or mortality [2].

As a middle molecular weight uremic toxin, β2-microglobulin (B2M) (11,800 Da) is produced by all cells expressing major histocompatibility class I. This protein is the major protein component of dialysis-related amyloidosis [3]. Since B2M is removed exclusively by the kidneys, concentration in the body increase in parallel with declines in glomerular filtration rate (GFR) in chronic kidney disease (CKD) and reach the highest levels among dialyzed patients [4-8]. Serum B2M level is also associated with several comorbid conditions, such as malignancy and inflammation. Higher serum B2M is well-known to be associated with higher mortality and rapid declines in kidney function among the general population [9, 10], non-dialyzed CKD patients [11] and patients on hemodialysis (HD) [12]. Indeed, the European Best Practice Guidelines have recommended the use of B2M as a marker for middle molecular weight uremic toxin and to maximize its removal in HD patients [13].

Serum B2M is also used as indicator of dialysis efficiency in PD patients. Notably, the efficiency of B2M removal is much lower in PD than in HD or on-line hemodiafiltration [14]. On the other hand, PD patients tend to maintain renal kidney function (RKF), as an important contributor to patient survival, more than HD patients [15]. B2M can accurately estimate RKF in dialyzed patients [7, 8, 16, 17]. In addition, we reported that serum B2M was higher in patients with a history of encapsulating peritoneal sclerosis, one of the most serious complications in PD therapy, as compared to those without [18, 19]. Serum B2M levels may thus have different impacts on patient outcome in PD patients from those in HD patients. Although a few reports have investigated the effects of serum B2M on mortality in PD patients, results have not been consistent, partially due to limited numbers of enrolled patients and shorter observational periods [20, 21].

The aim of this study was to investigate the impact of serum B2M levels on patient survival in PD patients, using data from a large-scale registry of dialysis patients in Japan.

Materials and methods

Study design and patient selection

The Japanese Society for Dialysis Therapy (JSDT) has conducted annual surveys of dialysis facilities throughout Japan. These surveys address epidemiological backgrounds, treatment conditions, and outcomes of treatment with dialysis. At the end of 2010, a total of 9,773 patients were undergoing PD in Japan [22]. Among these, we extracted 8,709 patients who were 18 years and older and had been undergoing PD for more than 3 months. The Medical Ethics Committee of the JSDT approved the study protocol (approval number: Dan-4, the date of approval: July 2, 2020). From an ethical perspective, all data were fully anonymized before being accessed. The requirement to obtain informed consent from the patients was waived because of the retrospective nature of the study. Instead, all individual participants were provided the opportunity to opt out of this study.

Measurements

Biochemical parameters including B2M, blood urea nitrogen (BUN), creatinine (Cr), serum albumin (Alb), C-reactive protein (CRP) and hemoglobin (Hb) were measured using standard laboratory techniques at each facility. We divided baseline B2M into four categories according to quartiles: <18.5 mg/L, 18.5 to <24.7 mg/L, 24.7 to <33.3 mg/L, and ≥33.3 mg/L. The dialysate-to-plasma ratio of creatinine (D/P Cr), obtained from a peritoneal equilibration test (PET), and total, renal, and PD Kt/V at initiation of PD were calculated at each facility [23].

Outcomes

Primary and secondary outcome was 9-year all-cause death and death from cardiovascular (CV) disease, respectively. This information was extracted from the data at the end of 2011 to 2019. CV death was defined as death caused by heart failure, acute myocardial infarction, arrhythmia, valvular disease, subarachnoid hemorrhage, cerebral hemorrhage, cerebral infarction, or sudden death.

Statistical analysis

Data are presented as mean ± standard deviation or median and interquartile range. Patients with and without serum B2M data were compared using Student’s t-test, the Wilcoxon rank-sum test, or the chi-square test, as appropriate. Subsequently, characteristics of the population were categorized by quartiles of serum B2M, and were compared by one-way analysis of variance or the non-parametric Kruskal-Wallis test for continuous variables, and the chi-square test for nominal variables. Multiple regression analysis was used to evaluate independent factors affecting serum B2M. Kaplan-Meier survival analysis was used to compare all-cause and CV mortality between patient groups divided according to serum B2M. Hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause death was assessed using Cox regression analysis. Standard sub-hazard ratios (SHRs) and 95%CIs for CV death were assessed using competing-risks regression analysis and considering non-CV death as the competing event. Competing-risks regression analysis was based on Fine and Gray’s proportional sub-hazard model [24] and modified for a STATA-specific presentation [25]. In these multivariate analyses, covariates were sex, age, dialysis duration, original disease, body mass index (BMI), laboratory data including BUN, Cr, Alb, CRP and Hb, comorbid disease and factors associated with PD managements including D/P Cr ratio, use of icodextrin, urine volume (UV) and history of PD peritonitis. Multiple imputation for missing values was performed in these multivariate analyses. The missing values of all covariates were imputed, assuming data were missing at random, with 20 imputations [26]. B2M, dialysis duration, CRP, and UV were markedly skewed, and log-transformed to normalize the distributions before analysis. We additionally explored the continuous, potentially nonlinear relationship between serum B2M and all-cause mortality by using restricted cubic spline models with five knots at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles. Subgroup analyses were performed for all baseline covariates including sex, age, dialysis duration, original disease, BMI, laboratory data, comorbid disease and factors associated with PD management at the beginning of follow-up. All covariates were divided into categorical groups and continuous variables were divided by medians except for UV. UV was divided into two groups about a cut-off value of 100 mL/day. Data were statistically analyzed using STATA version 16.0 (STATA Corporation, College Station, TX, USA). Values of P < 0.05 were considered significant.

Results

Fig 1 summarizes the process of data extraction. The original data set included a total of 8,709 patients aged 18 years or older and on PD for more than 3 months as of the end of 2010. We excluded 1,826 patients on combined therapy with PD and HD. For the remaining 6,883 patients, we first compared baseline characteristics between patients with and without serum B2M data (S1 Table). Data on serum B2M were available for 3,011 patients. Patients with B2M data displayed a higher prevalence of chronic glomerulonephritis (CGN) and nephrosclerosis as underlying diseases, fewer comorbidities of cerebral infarction, higher BUN, higher Cr, higher Alb, higher Hb and lower PD Kt/V as compared to those without B2M data. Of note, no effect on crude all-cause mortality was seen for the presence or absence of serum B2M data (HR 0.99; 95%CI, 0.92 to 1.06).

Fig 1

Patient selection flowchart.

Abbreviations: PD, peritoneal dialysis; HD, hemodialysis; B2M, β2 microglobulin.

Table 1 shows baseline characteristics of 3,011 patients (age, 63 ± 13 years; male, 61.4%; median dialysis duration, 31 months) with data for serum B2M. Underlying pathologies comprised CGN in 1,301 patients (43.2%), diabetic nephropathy in 856 (28.4%), nephrosclerosis in 362 (12.0%), polycystic kidney disease in 76 (2.5%), and other or unknown in 416 (13.8%). Patients with higher B2M were younger, had longer duration of dialysis, higher Cr, higher CRP, lower Hb, lower UV, lower renal Kt/V and higher PD Kt/V. Regarding underlying disease, CGN was more prevalent among the higher B2M group, whereas diabetic nephropathy and nephrosclerosis were more prevalent among the lower B2M group. Icodextrin users and patients with a history of PD-associated peritonitis were more prevalent among the higher B2M group.

Table 1

Baseline characteristics of 3011 PD patients by quartiles of serum B2M.

Variable	No. of missing value (%)	Whole group	B2M quartiles (mg/L)				P for trend
			< 18.5	18.5 to < 24.7	24.7 to < 33.3	≥ 33.3
Number (%)		3011	1188 (25.1%)	1126 (23.7%)	1176 (24.8%)	1252 (26.4%)
Age (years)	0 (0%)	63±13	64±14	64±13	62±13	60±13	<0.01
Male (%)	0 (0%)	1848 (61.4%)	494 (65.5%)	458 (60.6%)	450 (60.0%)	446 (59.4%	0.06
Dialysis duration (months)	0 (0%)	31 (15–54)	17 (9–31)	23 (12–41)	35 (20–55)	55 (33–90)	<0.01
Height (cm)	338 (11.2%)	160±9	160±9	160±9	160±10	161±9	0.69
BW (kg)	467 (15.5%)	60.1±12.4	60.5±12.6	59.7±11.8	60.4±12.8	59.7±12.5	0.43
BMI (kg/m2)	649 (21.6%)	23.2±3.7	23.3±3.6	23.1±3.6	23.3±3.8	23.0±3.9	0.39
Underlying disease	0 (0%)						<0.01
CGN (%)		1301 (43.2%)	278 (36.9%)	331 (43.8%)	313 (41.7%)	379 (50.5%)
Diabetic nephropathy (%)		856 (28.4%)	229 (30.4%)	209 (27.6%)	228 (30.4%)	190 (25.3%)
Nephrosclerosis (%)		362 (12.0%)	119 (15.8%)	98 (13.0%)	83 (11.1%)	62 (8.3%)
PKD (%)		76 (2.5%)	19 (2.5%)	19 (2.5%)	18 (2.4%)	20 (2.7%)
Others or unknown (%)		416 (13.8%)	109 (15.5%)	99 (13.1%)	108 (14.4%)	100 (13.3%)
Comorbidity
AMI	260 (8.6%)	182 (6.6%)	49 (7.1%)	54 (7.7%)	33 (4.8%)	46 (6.8%)	0.15
Cerebral hemorrhage	261 (8.7%)	88 (3.2%)	14 (2.1%)	26 (3.7%)	22 (3.2%)	26 (3.8%)	0.22
Cerebral infarction	259 (8.6%)	290 (10.5%)	64 (9.3%)	77 (11.0%)	70 (10.2%)	79 (11.6%)	0.53
Quadruple amputation	245 (8.1%)	25 (0.9%)	6 (0.9%)	4 (0.6%)	7 (1.0%)	8 (1.2%)	0.67
Laboratory data
B2M (mg/L)	0 (0%)	24.6 (18.4–33.2)	15.5 (12.9–17.0)	21.2 (19.9–22.9)	28.6 (26.4–30.8)	39.2 (36.0–44.1)	<0.01
BUN (mg/dL)	21 (0.7%)	54±15	53±16	57±14	57±15	54±14	<0.01
Cr (mg/dL)	15 (0.5%)	9.6±3.3	7.0±2.4	9.1±2.5	10.6±2.9	11.9±3.1	<0.01
Alb (g/L)	40 (1.3%)	3.4±0.5	3.5±0.5	3.4±0.5	3.3±0.5	3.4±0.6	<0.01
CRP (mg/dL)	357 (11.9%)	0.1 (0–0.5)	0.1 (0–0.3)	0.1 (0–0.4)	0.1 (0–0.5)	0.2 (0–0.6)	<0.01
Hb (g/dL)	33 (1.1%)	10.4±1.5	10.9±1.5	10.5±1.4	10.2±1.3	10.2±1.5	<0.01
PD related parameters
D/P Cr	1471 (48.9%)	0.66±0.13	0.64±0.14	0.66±0.13	0.69±0.13	0.65±0.13	<0.01
Use of icodextrin	569 (18.9%)	533 (21.8%)	61 (9.7%)	91 (14.4%)	156 (26.4%)	225 (38.3%)	<0.01
UV (mL/day)	1076 (35.7%)	650 (200–1030)	1010 (790–1430)	810 (550–1200)	500 (150–800)	50 (0–300)	<0.01
Renal Kt/V	1871 (62.1%)	0.5 (0.1–0.8)	0.9 (0.6–1.3)	0.6 (0.4–0.9)	0.3 (0.1–0.6)	0 (0–0.2)	<0.01
PD Kt/V	1658 (55.1%)	1.3 (1.0–1.7)	1.1 (0.7–1.6)	1.2 (0.9–1.5)	1.4 (1.1–1.7)	1.6 (1.4–1.9)	0.01
History of PD peritonitis	779 (25.9%)	387 (17.3%)	74 (13.3%)	106 (18.2%)	101 (18.5%)	106 (19.4%)	0.03

Date is shown as means ± SD or medians and interquartile ranges (IQR).

Abbreviations: PD, peritoneal dialysis; B2M, β2 microglobulin; BW, body weight; BMI, body mass index; CGN, chronic glomerulonephritis; PKD, polycystic kidney disease; AMI, acute myocardial infarction; BUN, blood urea nitrogen; Cr, creatinine; Alb, albumin; CRP, C-reactive protein; Hb, hemoglobin; D/P Cr, dialysate-to-plasma ratio of creatinine; UV, urinary volume.

Table 2 shows the results of multiple regression analysis. After multiple imputation for missing variables, sex, age, dialysis duration, diabetes, BMI, BUN, Cr, Alb, CRP, Hb, use of icodextrin and UV were all found to be independent factors affecting serum B2M. Among them, Cr and UV were strongly associated with serum B2M (t = 30.7, p < 0.01 and t = -12.8, p < 0.01, respectively).

Table 2

Contributing factors for serum B2M.

Variable	Unadjusted				Adjusted
	Regression Coefficient	t value	95% CI	p value	Regression Coefficient	t value	95% CI	p value
Male gender	-0.0316	-1.97	-0.0630 to -0.0001	0.049	-0.114	-9.19	-0.138 to -0.089	<0.01
Age (years)	-0.00355	-6.06	-0.00470 to -0.00240	<0.01	0.00246	5.01	0.00150 to 0.00343	<0.01
Ln Dialysis duration (months)	0.190	25.6	0.176 to 0.205	<0.01	0.0483	6.72	0.0342 to 0.0624	<0.01
Diabetes	-0.0206	-1.19	-0.0545 to 0.0134	0.23	0.0598	4.55	0.0340 to 0.0857	<0.01
BMI (kg/m2)	-0.00373	-1.62	-0.00827 to 0.00080	0.11	-0.0096	-5.33	-0.0131 to -0.0060	<0.01
History of AMI	-0.0170	-0.52	-0.0808 to 0.0468	0.60	0.0329	1.35	-0.0148 to 0.0806	0.18
History of cerebral hemorrhage	0.0833	1.81	-0.0068 to 0.1735	0.07	0.0314	0.91	-0.0362 to 0.0989	0.36
History of cerebral infarction	0.0297	1.13	-0.0220 to 0.0813	0.26	0.0023	0.11	-0.0381 to 0.0427	0.91
BUN (mg/dL)	0.00160	3.02	0.00056 to 0.00265	<0.01	-0.00224	-5.41	-0.00305 to -0.00143	<0.01
Cr (mg/dL)	0.0717	35.8	0.0678 to 0.0756	<0.01	0.0728	30.7	0.0682 to 0.0775	<0.01
Alb (g/L)	-0.0754	-4.92	-0.1055 to -0.0454	<0.01	-0.0931	-6.75	-0.1203 to -0.0660	<0.01
Ln CRP (mg/dL)	0.0214	5.13	0.0133 to 0.0296	<0.01	0.0110	3.08	0.0040 to 0.0181	<0.01
Hb (g/dL)	-0.0617	-11.8	-0.0719 to -0.0514	<0.01	-0.0209	-5.11	-0.0289 to -0.0129	<0.01
D/P Cr	0.0970	1.18	-0.0638 to 0.2579	0.24	-0.013	-0.23	-0.128 to 0.101	0.817
Use of icodextrin	0.251	12.4	0.211 to 0.290	<0.01	0.0600	3.91	0.0298 to 0.0902	<0.01
Ln UV (mL/day)	-0.0878	-26.9	-0.0942 to -0.0814	<0.01	-0.0433	-12.8	-0.0500 to -0.0366	<0.01
History of PD peritonitis	0.0475	2.02	0.0014 to 0.0936	0.04	0.0142	0.85	-0.0189 to 0.0473	0.40

Abbreviations: B2M, β2 microglobulin; CI, confidence interval; BMI, body mass index; AMI, acute myocardial infarction; BUN, blood urea nitrogen; Cr, creatinine; Alb, albumin; CRP, C reactive protein; Hb, hemoglobin; D/P Cr, dialysate-to-plasma ratio of creatinine; UV, urinary volume; PD, peritoneal dialysis.

During a median follow-up of 87 months, 2,054 patients transferred to other dialysis modalities such as combined therapy with PD and HD (n = 697) or HD directly (n = 1,357). A total of 1,235 (41.0%) died, including 437 patients (14.5%) from CV causes. Among them, 612 patients died after transfer to other dialysis modalities (n = 163 and n = 449 for patients transferred to combined therapy with PD and HD and those transferred to HD directly, respectively). Kaplan-Meier analysis showed that neither all-cause nor CV mortality differed significantly between four groups according to serum B2M (P = 0.35, P = 0.62, respectively; Fig 2A and 2B). Serum B2M was not associated with all-cause mortality in univariate analysis, whereas higher serum B2M was independently associated with higher all-cause mortality in the adjusted model (HR 1.07; 95%CI 0.93 to 1.22 and HR 1.64; 95%CI 1.33 to 2.03, respectively) in multivariate Cox regression analyses after multiple imputation for missing variables (Table 3). In addition, male sex, higher age, longer dialysis duration, diabetes, higher BUN, lower Cr, lower Alb, higher CRP and a greater number of comorbidities, including acute myocardial infarction (AMI), cerebral bleeding and cerebral infarction were associated with higher all-cause mortality. S2 Table shows the results of the Cox regression analysis after multiple imputation for missing variables treating serum B2M as a categorical variable. An unadjusted model revealed that all-cause mortality is constant regardless of serum B2M quantile. An adjusted model reveled that higher serum B2M (24.7 to <33.3 mg/L and ≥33.3 mg/L) were independently associated with higher all-cause mortality (HR 1.33; 95%CI 1.12 to 1.58 and HR 1.71; 95%CI 1.40 to 2.08, respectively), whereas lower serum B2M (<18.5 mg/L) did not affect all-cause mortality (HR 0.98; 95%CI 0.83 to 1.17). Fig 3 shows the results of restricted cubic spline curve. An unadjusted analysis revealed that all-cause mortality is constant regardless of serum B2M, whereas an adjusted analysis revealed a linear correlation between serum B2M and all-cause mortality. Serum B2M was not associated with CV mortality in univariate analysis, whereas higher serum B2M was independently associated with higher CV mortality in the adjusted model (SHR 1.07; 95%CI, 0.86 to 1.33 and SHR 1.48; 95%CI 1.02 to 2.16, respectively) in a multivariate competing-risks regression analysis after multiple imputation for missing variables (Table 3). Additionally, higher age, diabetes, higher CRP and higher UV were associated with higher CV mortality. S2 Table also shows the results of the competing-risks regression analysis after multiple imputation for missing variables treating serum B2M as a categorical variable. Both unadjusted and adjusted model revealed that CV mortality is constant regardless of serum B2M quantile.

Fig 2

Kaplan-Meier curve of all-cause (A) and CV mortality (B).

These parameters were compared between four groups according to serum B2M. Abbreviations: CV, cardiovascular; B2M, β2 microglobulin.

Table 3

HR and 95% CI of all-cause mortality and SHR and 95% CI of CV mortality.

	HR and 95% CI of all-cause mortality		SHR and 95% CI of CV mortality
	Unadjusted	Adjusted	Unadjusted	Adjusted
Male gender	1.17 (1.04 to 1.31)	1.46 (1.28 to 1.66)	1.21 (0.99 to 1.47)	1.23 (0.99 to 1.53)
Age [yr]	1.08 (1.07 to 1.08)	1.06 (1.06 to 1.07)	1.04 (1.04 to 1.05)	1.04 (1.03 to 1.05)
Ln Dialysis duration [months]	1.03 (0.97 to 1.10)	1.18 (1.09 to 1.27)	0.96 (0.87 to 1.05)	1.09 (0.96 to 1.24)
Diabetes	1.66 (1.48 to 1.87)	1.49 (1.32 to 1.69)	1.99 (1.65 to 2.41)	1.78 (1.45 to 2.19)
BMI [kg/m2]	0.98 (0.96 to 0.999)	1.00 (0.98 to 1.02)	1.01 (0.98 to 1.04)	1.01 (0.98 to 1.04)
BUN [mg/dL]	0.991 (0.987 to 0.994)	1.006 (1.001 to 1.010)	0.993 (0.987 to 0.999)	1.000 (0.993 to 1.006)
Cr [mg/dL]	0.88 (0.86 to 0.89)	0.88 (0.85 to 0.91)	0.92 (0.89 to 0.95)	0.96 (0.91 to 1.01)
Ln B2M [mg/L]	1.07 (0.93 to 1.22)	1.64 (1.33 to 2.03)	1.07 (0.86 to 1.33)	1.48 (1.02 to 2.16)
Alb [g/dL]	0.35 (0.31 to 0.39)	0.62 (0.54 to 0.70)	0.53 (0.44 to 0.63)	0.81 (0.65 to 1.02)
Ln CRP [mg/dL]	1.24 (1.20 to 1.28)	1.11 (1.07 to 1.14)	1.17 (1.11 to 1.24)	1.08 (1.02 to 1.14)
Hb [g/dL]	0.93 (0.90 to 0.97)	0.97 (0.93 to 1.02)	0.93 (0.87 to 0.99)	0.96 (0.89 to 1.03)
History of AMI	2.51 (2.08 to 3.03)	1.31 (1.08 to 1.60)	2.13 (1.57 to 2.89)	1.34 (0.96 to 1.89)
History of cerebral bleeding	1.82 (1.38 to 2.40)	1.34 (1.003 to 1.79)	1.68 (1.06 to 2.65)	1.17 (0.71 to 1.95)
History of cerebral infarction	2.53 (2.17 to 2.96)	1.26 (1.07 to 1.48)	1.70 (1.29 to 2.24)	1.03 (0.77 to 1.38)
D/P Cr ratio	2.53 (1.35 to 4.75)	0.88 (0.46 to 1.68)	1.63 (0.53 to 4.98)	0.70 (0.27 to 1.84)
Use of icodextrin	1.13 (0.97 to 1.32)	1.04 (0.89 to 1.22)	1.11 (0.86 to 1.43)	1.03 (0.77 to 1.36)
Ln UV [mL/day]	0.98 (0.96 to 1.01)	0.98 (0.95 to 1.02)	1.05 (0.99 to 1.11)	1.06 (1.001 to 1.13)
History of PD peritonitis	1.29 (1.09 to 1.52)	0.93 (0.79 to 1.10)	1.13 (0.85 to 1.51)	0.94 (0.70 to 1.26)

Abbreviations: HR, hazard ratio; CI, confidence interval; SHR, sub-hazard ratio; CV, cardiovascular; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; B2M, β2 microglobulin; Alb, albumin; CRP, C-reactive protein; Hb, hemoglobin; AMI, acute myocardial infarction; D/P Cr, dialysate-to-plasma ratio of creatinine; UV, urinary volume; PD, peritoneal dialysis.

Fig 3

HRs for all-cause mortality derived from univariate [A] and multivariate analysis [B].

Lines represent HRs and 95% CIs based on restricted cubic splines for serum B2M levels with five knots at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles. Abbreviations: HR, hazard ratio.

Fig 4 shows results of subgroup analysis focused on associations between serum B2M and all-cause mortality. UV and a history of AMI significantly affected the impact of serum B2M on all-cause mortality (HR 1.63; 95%CI 1.08 to 2.48 and HR 0.84; 95%CI 0.33 to 2.17 for patients with UV ≥ 100 mL/day and those with UV < 100 mL/day, respectively, interaction P = 0.03 and HR 1.70; 95%CI 0.57 to 5.09 and HR 1.78; 95%CI 1.17 to 2.71, for patients with a history of AMI and those without a history of AMI, respectively, interaction P = 0.02). However, it should be taken into account that the number of patients with UV < 100 mL/day (n = 362) and those with a history of AMI (n = 182) were small.

Fig 4

Subgroup analysis for the association between serum B2M and all-cause mortality.

Dots and bars correspond to adjusted HRs and 95% CIs for all-cause death. Abbreviations: B2M, β2 microglobulin; HR, hazard ratio; CI, confidence interval; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; Alb, albumin; CRP, C-reactive protein; Hb, hemoglobin; AMI, acute myocardial infarction; D/P Cr, dialysate-to-plasma ratio of creatinine; UV, urinary volume; PD, peritoneal dialysis; HD, hemodialysis.

We conducted subgroup Cox regression analysis for all-cause mortality among patients continued PD, those transferred to combined therapy with PD and HD and those directly transferred to HD, separately (Table 4). In univariate Cox regression analyses, higher serum B2M was associated with higher all-cause mortality only among patients continued PD (HR 1.33; 95%CI 1.12 to 1.58, HR 1.26; 95%CI 0.83 to 1.89 and HR 1.18; 95%CI 0.94 to 1.48 for patients continued PD, those transferred to combined therapy and those transferred to HD directly, respectively). In multivariate Cox regression analyses after multiple imputation for missing variables, higher serum B2M was independently associated with higher all-cause mortality in all groups (HR 1.48; 95%CI 1.10 to 2.00, HR 2.26; 95%CI 1.17 to 4.33 and HR 2.04; 95%CI 1.42 to 2.92 for patients continued PD, those transferred to combined therapy and those transferred to HD directly, respectively). Dialysis modalities did not affect the association between serum B2M and mortality (interaction P = 0.18, Fig 4). Kaplan-Meier analysis involving only patients continued PD revealed that all-cause mortality in the higher B2M group was significantly higher compared to that in the lower B2M groups especially during 36 months (log-rank P = 0.02; Fig 5).

Table 4

HR and 95% CI of all-cause for each dialysis modality.

	Patients continued PD		Patients transferred to combined therapy		Patients directly transferred to HD
	Unadjusted	Adjusted	Unadjusted	Adjusted	Unadjusted	Adjusted
Male gender	1.35 (1.15 to 1.58)	1.31 (1.10 to 1.57)	1.76 (1.23 to 2.53)	1.96 (1.32 to 2.93)	1.26 (1.04 to 1.53)	1.60 (1.28 to 1.99)
Age [yr]	1.04 (1.03 to 1.05)	1.03 (1.03 to 1.04)	1.08 (1.06 to 1.10)	1.08 (1.06 to 1.10)	1.08 (1.07 to 1.09)	1.07 (1.06 to 1.08)
Ln Dialysis duration [months]	1.04 (0.96 to 1.12)	1.12 (1.02 to 1.24)	1.08 (0.91 to 1.29)	1.16 (0.93 to 1.45)	1.04 (0.94 to 1.15)	1.25 (1.09 to 1.43)
Diabetes	1.59 (1.35 to 1.88)	1.41 (1.18 to 1.70)	1.84 (1.34 to 2.54)	1.53 (1.06 to 2.22)	1.76 (1.46 to 2.13)	1.69 (1.37 to 2.09)
BMI [kg/m2]	1.02 (0.997 to 1.05)	1.02 (0.99 to 1.05)	1.04 (0.996 to 1.09)	1.04 (0.98 to 1.10)	0.98 (0.95 to 1.01)	0.98 (0.95 to 1.01)
BUN [mg/dL]	0.999 (0.993 to 1.004)	1.005 (0.999 to 1.011)	1.006 (0.995 to 1.017)	1.013 (0.999 to 1.025)	0.996 (0.989 to 1.002)	1.012 (1.004 to 1.019)
Cr [mg/dL]	0.96 (0.93 to 0.98)	0.96 (0.91 to 1.01)	0.94 (0.90 to 0.99)	0.90 (0.83 to 0.98)	0.89 (0.86 to 0.92)	0.86 (0.81 to 0.90)
Ln B2M [mg/L]	1.33 (1.12 to 1.58)	1.48 (1.10 to 2.00)	1.26 (0.83 to 1.89)	2.26 (1.17 to 4.33)	1.18 (0.94 to 1.48)	2.04 (1.42 to 2.92)
Alb [g/dL]	0.39 (0.34 to 0.45)	0.57 (0.48 to 0.69)	0.65 (0.45 to 0.93)	0.89 (0.60 to 1.30)	0.39 (0.32 to 0.47)	0.64 (0.50 to 0.81)
Ln CRP [mg/dL]	1.20 (1.15 to 1.25)	1.06 (1.01 to 1.11)	1.20 (1.11 to 1.31)	1.14 (1.04 to 1.24)	1.22 (1.16 to 1.28)	1.12 (1.06 to 1.18)
Hb [g/dL]	0.89 (0.84 to 0.93)	0.95 (0.90 to 1.01)	0.95 (0.85 to 1.06)	1.02 (0.90 to 1.16)	0.92 (0.86 to 0.98)	0.94 (0.88 to 1.02)
History of AMI	2.01 (1.55 to 2.59)	1.38 (1.06 to 1.80)	2.36 (1.34 to 4.17)	1.30 (0.69 to 2.43)	2.67 (1.92 to 3.72)	1.20 (0.84 to 1.71)
History of cerebral bleeding	1.88 (1.31 to 2.70)	1.22 (0.82 to 1.81)	2.45 (1.15 to 5.24)	2.09 (0.92 to 4.75)	1.29 (0.76 to 2.20)	1.11 (0.64 to 1.93)
History of cerebral infarction	2.15 (1.75 to 2.64)	1.34 (1.08 to 1.67)	2.36 (1.42 to 3.91)	1.36 (0.77 to 2.39)	2.06 (1.55 to 2.73)	1.04 (0.77 to 1.40)
D/P Cr ratio	3.04 (1.29 to 7.15)	1.12 (0.48 to 2.64)	0.45 (0.10 to 2.01)	0.55 (0.11 to 2.87)	4.69 (1.61 to 13.69)	0.86 (0.31 to 2.42)
Use of icodextrin	1.33 (1.07 to 1.64)	0.97 (0.77 to 1.23)	1.14 (0.76 to 1.72)	1.04 (0.67 to 1.61)	1.08 (0.84 to 1.39)	1.07 (0.81 to 1.41)
Ln UV [mL/day]	0.97 (0.94 to 1.003)	0.99 (0.95 to 1.04)	1.00 (0.92 to 1.07)	1.02 (0.92 to 1.13)	1.02 (0.97 to 1.07)	1.01 (0.95 to 1.08)
History of PD peritonitis	1.30 (1.03 to 1.64)	1.08 (0.87 to 1.36)	1.22 (0.74 to 2.00)	0.93 (0.56 to 1.54)	1.32 (1.01 to 1.71)	0.90 (0.69 to 1.17)

Abbreviations: HR, hazard ratio; CI, confidence interval; PD, peritoneal dialysis; HD, hemodialysis; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; B2M, β2 microglobulin; Alb, albumin; CRP, C-reactive protein; Hb, hemoglobin; AMI, acute myocardial infarction; D/P Cr, dialysate-to-plasma ratio of creatinine; UV, urinary volume.

Fig 5

Kaplan-Meier curve of all-cause mortality among patients continued PD.

This parameter was compared between four groups according to serum B2M. Abbreviations: B2M, β2 microglobulin.

Discussion

This observational study using a large-scale registry of 3,011 Japanese PD patients over a 9-year follow-up revealed that higher serum B2M was independently associated with all-cause mortality. The associations between higher serum B2M and higher all-cause mortality were already certified in both non-dialyzed CKD [9-11] and HD patients [12]. However, the findings contrast with those of previous studies conducted in PD patients. Koh et al. [20] reported that higher serum B2M was associated with higher all-cause mortality among 771 Korean prevalent PD patients. However, the effect of higher serum B2M disappeared after adjusting for residual renal clearance, calculated as the mean of creatinine and urea clearances. Chang et al. [21] also reported that an association between higher serum B2M and higher mortality disappeared after adjusting for residual renal clearance applying the same method among 725 Korean incident PD patients. Conversely, the increased risk of all-cause death in patients with lower serum B2M became more evident even after adjusting for several confounding factors including RKF. RKF is well known as a strong predictor of mortality among PD patients [27, 28], and B2M can accurately estimate RKF in dialyzed patients [7, 8, 16, 17]. Indeed, UV was the strongest independent factor affecting serum B2M in our multiple regression analysis. In addition, a positive association between higher serum B2M and higher mortality was more prominent among patients with preserved RKF and there was a significant interaction, as well as the results of previous two studies [20, 21]. Based on the above, RKF is thought to be most important factor in the effect of serum B2M on mortality.

Meanwhile, serum B2M was not associated with all-cause or CV mortality in our univariate analyses. We speculated that higher serum B2M is associated with higher mortality, because it reflects not only the accumulation of middle molecular weight uremic toxins, but also inflammation or declines in RKF. Although the mechanisms responsible for this observation of univariate analysis remain unclear, malnutrition and immunological disturbance might be involved. B2M is synthesized and shed mainly by lymphocytes [29, 30], and its count is one of the most commonly used nutritional parameters [31]. However, no definitive proof of alterations in the generation or metabolism of B2M has been seen from nutritional status, especially in dialyzed patients. Given the possibility that the association between serum B2M and mortality is nonlinear, we conducted multivariate analysis treating serum B2M as a categorical variable and analysis using restricted cubic spline curve and found that there was no U-shaped association. At least, this finding can lead to the consequence that serum B2M per se had no predictive value for patient outcome in PD patients. We conducted subgroup analysis for all-cause mortality among patients continued PD, those transferred to combined therapy with PD and HD and those directly transferred to HD, separately, and found that higher serum B2M was associated with higher all-cause mortality in univariate analysis only among patients continued PD. Although these data could suggest that serum B2M reflects patient survival before transfer to other dialysis modality, further study is needed to clarify the effects of serum B2M on mortality in PD patients.

In multiple regression analysis, Cr and dialysis duration were strongly associated with serum B2M. Additionally, both were independent prognostic factor for all-cause death in multivariate Cox regression analysis. Cr was reported to be positively correlated with serum B2M not only in non-dialyzed patients [32, 33] but also in dialyzed patients [16, 20]. Recent systematic review including four studies of dialyzed patients, two focused on PD and two focused on HD, revealed that higher circulating B2M was associated significantly with higher risk of all-cause mortality [34], whereas several large cohort studies of dialyzed patients revealed that Cr was inversely correlated with mortality risk [35, 36]. This discrepancy could be explained by reverse epidemiology [37]. Since Cr reflects muscle mass or meat ingestion and/or the degree of dialysis efficiency in dialyzed patients, harmful effect of higher Cr in the general population is completely reversed in patients on dialysis. On the other hand, an independent association between serum B2M and dialysis duration has been already demonstrated both in PD [20] and HD patients [12]. Additionally, these studies revealed that longer dialysis duration was independently associated with higher mortality. Although the detailed mechanisms are unclear, it is speculated that not only RKF declines but also inflammation, malnutrition, left ventricular hypertrophy or immune dysfunction become prominent in patients with longer dialysis duration and therefore longer dialysis duration could be independently associated with poor patient outcome even after adjustment for known risk factors.

Strengths of our study include the examination of a large cohort of PD patients, allowing for more definite results with extensive adjustments and subgroup analyses. However, several limitations to the study should be discussed. First, the observational design allowed only limited conclusions. In particular, we cannot prove any cause-and-effect relationships. Second, serum B2M and other laboratory data were measured only at baseline, so we could not determine the effects of changes from baseline during follow-up using time-dependent analyses. Third, we used UV as a surrogate marker of RKF. Since UV has large variation from dietary intake or non-renal output, renal clearance of urea and creatinine could better reflect RKF. Additionally, one-third of enrolled patients did not have UV data. However, we could not use Kt/V as confounding factor because approximately two-thirds of patients did not have this data.

Conclusion

Using a large-scale registry of 3,011 Japanese PD patients, higher serum B2M was independently associated with higher all-cause mortality especially among patients with preserved UV. These data suggest that B2M contributes significantly to worse patient outcome and RKF significantly affects this relationship. On the contrary, serum B2M per se had no predictive value for patient outcome in this population. Further investigations are needed to validate the clinical utility of serum B2M among PD patients.

Comparisons of baseline characteristics between patients with and without serum B2M data.

(DOCX)

Click here for additional data file.

HR and 95% CI of all-cause mortality and SHR and 95% CI of CV mortality, with analysis using serum B2M as a categorical variable.

(DOCX)

Click here for additional data file.

26 Jan 2022

The reviewers proposed several important queries. Please respond to all of the concerns.

Please submit your revised manuscript by Mar 10 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kojiro Nagai

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3. Thank you for stating the following in the Competing Interests section:

"I have read the journal's policy and the authors of this manuscript have the following competing interests: Y.M. received honoraria from Baxter International, Inc. and Terumo Corporation. No other authors have any conflicts of interest to declare."

We note that you received funding from a commercial source: Baxter International, Inc. and Terumo Corporation

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: ""This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Additional Editor Comments:

Is it OK to conclude that serum b2M was independently associated with CV mortality?

I do understand the efforts to analyze the relationship between b2M and mortality in a large scale cohort by using multiple methods of analysis.

However, it seems that the association between b2M and CV mortality was not constant among these methods (S2 Table).

In “limitation”, it is better to describe that one third of enrolled patients did not have UV data.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors revealed that B2M levels contributes significantly to all-cause and CV mortality, and residual kidney function significantly affect this relationship in patients with PD. These findings were reasonable, but several revisions would be required.

1. The authors should show Kaplan-Meier curve for B2M levels.

2. Higher serum B2M levels was shown as a significant risk factor for mortality, but the impact seems to be not big, according to the results from Figure 2 and Table 3. For example, if compare 1st and 3rd quartile for B2M levels (18.5 mg/l and 33.3 mg/l, respectively), Ln(18.5) = 2.91 and Ln(33.3) = 3.50, hence change of drastic B2M levels increased event risk only 1.35 fold (according to the results from Table 3). How do the authors think about it?

3. It was a bit strange about relationship among serum creatinine levels, serum B2M levels and all-cause mortality risk. Higher serum creatinine levels was related to higher B2M levels strongly, but lower creatinine levels was a higher all-cause mortality risk although higher B2M levels was a higher all-cause mortality risk. Please describe your consideration in the discussion part.

4. The authors described that serum B2M levels was associated with all-cause mortality among patients with UV > 100 ml/day and patients without a history of AMI (Fig 3). However, I think it is difficult to conclude these results. The 95% CI range for patients with history of AMI was quite wide; I guess very small number of patients had the history. Also, wide range of 95% CI was overlap between patients with UV > 100 ml/day and with UV < 100 ml/day. Interaction P for UV and history of AMI seems to be small, but multiplicity of testing should be considered. Can the authors show number of patients and events in each group?

Reviewer #2: Maruyama et al. reported a higher mortality rate in peritoneal dialysis patients with high serum β2MG levels. Although the present manuscript is important in examining the significance of β2MG levels in peritoneal dialysis patients, more concise analysis of its interpretation is needed.

1. Kaplan-Meier curves for the four groups should be developed and analyzed for mortality and CV events.

2. Since the β2MG level is affected by the duration of dialysis, the duration of dialysis seems to define the mortality and CV events after all. The authors should discuss the association between serum β2MG and dialysis duration.

3. If the analysis includes the group of patients who changed to HD+PD combination therapy or HD alone and the group of patients who treated with PD alone, it is necessary to analyze them separately.

4. Why is there no association between β2MG level and all-cause mortality in the group with UV less than 100 ml in Figure 3?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

8 Mar 2022

Response to Reviewers

The comments from the reviewers proved very helpful. We have worked through each of the comments to address the issues raised, and have made detailed point-by-point responses to each of the comments provided by the reviewers. All authors have contributed to this revised manuscript and agree to this re-submission.

First of all, we revised all results, Tables and Figures because some erroneous data of underlying disease were discovered in original database.

Editor Comments:

Is it OK to conclude that serum b2M was independently associated with CV mortality?

I do understand the efforts to analyze the relationship between b2M and mortality in a large scale cohort by using multiple methods of analysis.

However, it seems that the association between b2M and CV mortality was not constant among these methods (S2 Table).

RESPONSE: Thank you for raising this important point. As suggested, the effect of higher serum B2M on all-cause mortality was statistically significant but not intense. On the other hand, the significant association between serum B2M and CV mortality was found only in analysis treating serum B2M as a continuous variable and disappeared in analysis treating serum B2M as a categorical variable. We have added mention of this in the Abstract and Discussion.

In “limitation”, it is better to describe that one third of enrolled patients did not have UV data.

RESPONSE: Thank you for a helpful comment. As suggested, we have added the following sentences to the Limitations section: “Additionally, approximately one-third of patients did not have UV data.”

Reviewer #1: The authors revealed that B2M levels contributes significantly to all-cause and CV mortality, and residual kidney function significantly affect this relationship in patients with PD. These findings were reasonable, but several revisions would be required.

1. The authors should show Kaplan-Meier curve for B2M levels.

RESPONSE: Thank you for this helpful comment. As suggested, we conducted new analysis using Kaplan-Meier curve and confirmed that neither all-cause nor CV mortality differed significantly between four groups according to serum B2M (log-rank P=0.35, log-rank P=0.62, respectively; Fig 2A and 2B).

2. Higher serum B2M levels was shown as a significant risk factor for mortality, but the impact seems to be not big, according to the results from Figure 2 and Table 3. For example, if compare 1st and 3rd quartile for B2M levels (18.5 mg/l and 33.3 mg/l, respectively), Ln(18.5) = 2.91 and Ln(33.3) = 3.50, hence change of drastic B2M levels increased event risk only 1.35 fold (according to the results from Table 3). How do the authors think about it?

RESPONSE: Thank you for raising this important point. As Editor has also suggested, the effect of higher serum B2M on mortality was statistically significant but not intense. Multivariate analysis treating serum B2M as a categorical variable and analysis using restricted cubic spline curve were conducted toward the detection of nonlinear or U-shaped association, and we confirmed a linear association. The reason for a low impact of serum B2M on mortality is at present unclear. However, we believed that our study included one of the largest cohort of PD patients, allowing for more definite results with extensive adjustments. We have revised Conclusion both in Abstract and text.

3. It was a bit strange about relationship among serum creatinine levels, serum B2M levels and all-cause mortality risk. Higher serum creatinine levels was related to higher B2M levels strongly, but lower creatinine levels was a higher all-cause mortality risk although higher B2M levels was a higher all-cause mortality risk. Please describe your consideration in the discussion part.

RESPONSE: Thank you for this helpful comment. We carefully checked the results of regression analysis and confirmed that Cr was positively associated with serum B2M. This finding is in accordance with previous reports. Cr was reported to be positively correlated with serum B2M not only in non-dialyzed patients [Wu HC et al. J Clin Lab Anal 31:e22056,2017 and Juraschek SP et al. Clin J Am Soc Nephrol 8:584-92,2013] but also in dialyzed patients [Koh ES et al. Am J Nephrol 42:91-8,2015 and Shafi T et al. Kidney Int 89:1099-110,2016]. Recent systematic review including four studies of dialyzed patients, two focused on PD and two focused on HD, revealed that higher circulating B2M was associated significantly with higher risk of all-cause mortality [Zhang J et al. Ther Apher Dial Online ahead of print], whereas several large cohort studies of dialyzed patients revealed that Cr was inversely correlated with mortality risk [Fink JC et al. Am J Kidney Dis 34:694-701,1999, Xue JL et al. Kidney Int 61:741-6,2002]. This discrepancy could be explained by reverse epidemiology [Kalantar-Zadeh K et al. Kidney Int 63:793-808,2003]. Since Cr reflects muscle mass or meat ingestion and/or the degree of dialysis efficiency in dialyzed patients, harmful effect of higher Cr in the general population is completely reversed in patients on dialysis. We have added this to the Discussion.

4. The authors described that serum B2M levels was associated with all-cause mortality among patients with UV > 100 ml/day and patients without a history of AMI (Fig 3). However, I think it is difficult to conclude these results. The 95% CI range for patients with history of AMI was quite wide; I guess very small number of patients had the history. Also, wide range of 95% CI was overlap between patients with UV > 100 ml/day and with UV < 100 ml/day. Interaction P for UV and history of AMI seems to be small, but multiplicity of testing should be considered. Can the authors show number of patients and events in each group?

RESPONSE: Thank you for raising this important point. As suggested, assessing the significance of HR for mortality is inappropriate, because the number of patients with UV 100 mL/day (n= 362) and those with a history of AMI (n=182) were small. Since the chief aim of this analysis was to determine the effect of several confounding factors on the association between serum B2M and mortality, we totally revised the description of the results of subgroup analysis as follows: “UV and a history of AMI significantly affected the impact of serum B2M on all-cause mortality (HR 1.63; 95%CI 1.08 to 2.48 and HR 0.84; 95%CI 0.33 to 2.17 for patients with UV ≥ 100 mL/day and those with UV < 100 mL/day, respectively, interaction P = 0.03 and HR 1.70; 95%CI 0.57 to 5.09 and HR 1.78; 95%CI 1.17 to 2.71, for patients with a history of AMI and those without a history of AMI, respectively, interaction P = 0.02). However, it should be taken into account that the number of patients with UV < 100 mL/day (n= 362) and those with a history of AMI (n=182) were small.”

Reviewer #2: Maruyama et al. reported a higher mortality rate in peritoneal dialysis patients with high serum β2MG levels. Although the present manuscript is important in examining the significance of β2MG levels in peritoneal dialysis patients, more concise analysis of its interpretation is needed.

1. Kaplan-Meier curves for the four groups should be developed and analyzed for mortality and CV events.

RESPONSE: Thank you for this helpful comment. As the other Reviewer also suggested, we conducted new analysis using Kaplan-Meier curve and confirmed that neither all-cause nor CV mortality differed significantly between four groups according to serum B2M (log-rank P=0.35, log-rank P=0.62, respectively; Fig 2A and 2B).

2. Since the β2MG level is affected by the duration of dialysis, the duration of dialysis seems to define the mortality and CV events after all. The authors should discuss the association between serum β2MG and dialysis duration.

RESPONSE: Thank you for this helpful comment. An independent association between serum B2M and dialysis duration has been already demonstrated both in PD [Koh ES et al. Am J Nephrol 42:91-8,2015] and HD patients [Cheung AK et al. J Am Soc Nephrol 17:546–55,2006]. Additionally, these studies revealed that longer dialysis duration was independently associated with higher mortality. Although the detailed mechanisms are unclear, it is speculated that not only RKF declines but also inflammation, malnutrition, left ventricular hypertrophy or peritoneal deterioration become prominent in patients with longer dialysis duration and therefore longer dialysis duration was independently associated with poor patient outcome even after adjustment for known risk factors. We have added this to the Discussion.

3. If the analysis includes the group of patients who changed to HD+PD combination therapy or HD alone and the group of patients who treated with PD alone, it is necessary to analyze them separately.

RESPONSE: Thank you for raising this important point. We completely agree with the idea that dialysis modalities were important factors contributing to the association between serum B2M and mortality. During a median follow-up of 87 months, 2,053 patients transferred to other dialysis modalities such as combined therapy with PD and HD (n=697) or HD directly (n=1,357). A total of 1,235 (41.0%) died, including 437 patients (14.5%) from CV causes. Among them, 612 patients died after transfer to other dialysis modalities (n=163 and n=449 for patients transferred to combined therapy with PD and HD and those transferred to HD directly, respectively). As suggested, we conducted subgroup Cox regression analysis for all-cause mortality among patients continued PD, those transferred to combined therapy with PD and HD and those directly transferred to HD, separately (Table 4). In univariate Cox regression analyses, higher serum B2M was associated with higher all-cause mortality only among patients continued PD (HR 1.33; 95%CI 1.12 to 1.58, HR 1.26; 95%CI 0.83 to 1.89 and HR 1.18; 95%CI 0.94 to 1.48 for patients continued PD, those transferred to combined therapy and those transferred to HD directly, respectively). In multivariate Cox regression analyses after multiple imputation for missing variables, serum B2M was independently associated with higher all-cause mortality in all groups (HR 1.48; 95%CI 1.10 to 2.00, HR 2.26; 95%CI 1.17 to 4.33 and HR 2.04; 95%CI 1.42 to 2.92 for patients continued PD, those transferred to combined therapy and those transferred to HD directly, respectively). Dialysis modalities did not affect the association between serum B2M and mortality (interaction P=0.18, Fig 4). Kaplan-Meier analysis involving only patients continued PD revealed that all-cause mortality in the higher β2-M group was significantly higher compared to that in the lower β2-M groups especially during 36 months (log-rank P=0.02, Fig 5). Although these data could suggest that serum B2M reflects patient survival before transfer to other dialysis modality, further study is needed to clarify the effects of serum B2M on mortality in PD patients. We have added this to the Results and the Discussion.

4. Why is there no association between β2MG level and all-cause mortality in the group with UV less than 100 ml in Figure 3?

RESPONSE: Thank you for raising this important point. As other Reviewer suggested, assessing the significance of HR for mortality in subgroup analysis was inappropriate, because the 95% CI range for patients with UV < 100 mL/day was quite wide because of small number of patients (n=362). Since the chief aim of this analysis was to determine the effect of several confounding factors on the association between serum B2M and mortality, we totally revised the description of the results of subgroup analysis as follows: “UV and a history of AMI significantly affected the impact of serum B2M on all-cause mortality (HR 1.63; 95%CI 1.08 to 2.48 and HR 0.84; 95%CI 0.33 to 2.17 for patients with UV ≥ 100 mL/day and those with UV < 100 mL/day, respectively, interaction P = 0.03 and HR 1.70; 95%CI 0.57 to 5.09 and HR 1.78; 95%CI 1.17 to 2.71, for patients with a history of AMI and those without a history of AMI, respectively, interaction P = 0.02). However, it should be taken into account that the number of patients with UV < 100 mL/day (n= 362) and those with a history of AMI (n=182) were small.”

Submitted filename: Response to Reviewers PONE D 22 00429.docx

Click here for additional data file.

30 Mar 2022

Association between serum β2-microglobulin and mortality in Japanese peritoneal dialysis patients: a cohort study

PONE-D-22-00429R1

Dear Dr. Maruyama,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kojiro Nagai

Academic Editor

PLOS ONE

Additional Editor Comments (optional):　All comments have been addressed.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All comments have been addressed. I have no further comments. I think the manuscript would be acceptable.

Reviewer #2: The authors revised nicely. This research will cotribute to understand the status of PD patients.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

6 Apr 2022

PONE-D-22-00429R1

Association between serum β2-microglobulin and mortality in Japanese peritoneal dialysis patients: a cohort study

Dear Dr. Maruyama:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kojiro Nagai

Academic Editor

PLOS ONE